On March 1, 2023 Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D. "the Company") reported the status of acquisition of its own shares as stated below (Press release, Astellas, MAR 1, 2023, View Source [SID1234627921]). The acquisition was implemented pursuant to the provision of its Articles of Incorporation in accordance with Article 459, paragraph 1 of the Companies Act.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Particulars

Class of shares acquired:　　　　 　 Common stock of the Company

Total number of shares acquired:　　15,153,600 shares

Total amount of acquisition cost:　　 29,023,551,450 yen

Period of acquisition:　　　　　　　 From February 7, 2023 to February 28, 2023

Method of acquisition:　　　　　 　 Market purchase on the Tokyo Stock Exchange

(Reference)

Details of the resolution at the meeting of the Board of Directors (announced on February 6, 2023)
(1) Class of shares to be acquired:　　　　 Common stock of the Company
(2) Total number of shares to be acquired:　Up to 29 million shares
(Ratio to the total number of shares outstanding [excluding treasury stock]: 1.59%)
(3) Total amount of acquisition cost:　　　 Up to 50 billion yen
(4) Period of acquisition:　　　　　　　　 From February 7, 2023 to March 24, 2023
(5) Method of acquisition:　　　　　　　　 Market purchase on the Tokyo Stock Exchange

Accumulated Company’s own shares acquired through February 28, 2023, pursuant to the above board resolution
(1) Total number of shares acquired:　　　 15,153,600 shares
(2) Total amount of acquisition cost:　　　 29,023,551,450 yen